{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T12:55:49Z","timestamp":1788612949300,"version":"build-2803163510"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T00:00:00Z","timestamp":1698278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T00:00:00Z","timestamp":1698278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004046","name":"Karen Elise Jensens Fond","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/501100004046","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008628","name":"Institut for Klinisk Medicin, Aarhus Universitet","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100008628","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005747","name":"A.P. M\u00f8ller og Hustru Chastine Mc-Kinney M\u00f8llers Fond til almene Formaal","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/501100005747","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-023-00931-6","type":"journal-article","created":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T07:02:23Z","timestamp":1698303743000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Proteomics uncovers molecular features for relapse risk stratification in patients with diffuse large B-cell lymphoma"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5089-3271","authenticated-orcid":false,"given":"Maja","family":"Ludvigsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3582-3728","authenticated-orcid":false,"given":"Amanda Jessica","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Beck","family":"Enemark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trine Engelbrecht","family":"Hybel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marja-Liisa","family":"Karjalainen-Lindsberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Beiske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette","family":"Bjerre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars M\u00f8ller","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Holte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8265-511X","authenticated-orcid":false,"given":"Sirpa","family":"Lepp\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit Meszaros","family":"J\u00f8rgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3459-7429","authenticated-orcid":false,"given":"Bent","family":"Honor\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,26]]},"reference":[{"key":"931_CR1","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/S0140-6736(12)60605-9","volume":"380","author":"KR Shankland","year":"2012","unstructured":"Shankland KR, Armitage JO, Hancock BW. Non-Hodgkin lymphoma. Lancet [Internet]. 2012;380:848\u201357. https:\/\/doi.org\/10.1016\/S0140-6736(12)60605-9.","journal-title":"Lancet [Internet]"},{"key":"931_CR2","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","volume":"9","author":"M Pfreundschuh","year":"2008","unstructured":"Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9:105\u201316.","journal-title":"Lancet Oncol"},{"key":"931_CR3","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1056\/NEJMra2027612","volume":"384","author":"DL Longo","year":"2021","unstructured":"Longo DL, Sehn LH, Salles G. Diffuse Large B-Cell Lymphoma. N Engl J Med. 2021;384:842\u201358.","journal-title":"N Engl J Med"},{"key":"931_CR4","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, et al. Outcomes in refractory diffuse large B-cell lymphoma: Results from the international SCHOLAR-1 study. Blood. 2017;130:1800\u20138.","journal-title":"Blood."},{"key":"931_CR5","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"AA Alizadeh","year":"2000","unstructured":"Alizadeh AA, Elsen MB, Davis RE, Ma CL, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503\u201311.","journal-title":"Nature"},{"key":"931_CR6","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1182\/blood-2013-11-536433","volume":"123","author":"DW Scott","year":"2014","unstructured":"Scott DW, Wright GW, Williams PM, Lih CJ, Walsh W, Jaffe ES, et al. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood. 2014;123:1214\u20137.","journal-title":"Blood"},{"key":"931_CR7","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1200\/JCO.2009.26.3947","volume":"28","author":"S Barrans","year":"2010","unstructured":"Barrans S, Crouch S, Smith A, Turner K, Owen R, Patmore R, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol. 2010;28:3360\u20135.","journal-title":"J Clin Oncol"},{"key":"931_CR8","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1158\/1541-7786.MCR-20-0466","volume":"19","author":"M Deng","year":"2021","unstructured":"Deng M, Xu-Monette ZY, Pham LV, Wang X, Tzankov A, Fang X, et al. Aggressive B-cell lymphoma with MYC\/TP53 dual alterations displays distinct clinicopathobiological features and response to novel targeted agents. Mol Cancer Res. 2021;19:249\u201360.","journal-title":"Mol Cancer Res"},{"key":"931_CR9","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1182\/bloodadvances.2020001518","volume":"4","author":"S Lepp\u00e4","year":"2020","unstructured":"Lepp\u00e4 S, J\u00f8rgensen J, Tierens A, Meriranta L, \u00d8stlie I, de Nully Brown P, et al. Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis. Blood Adv. 2020;4:1906\u201315.","journal-title":"Blood Adv"},{"key":"931_CR10","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1093\/annonc\/mds621","volume":"24","author":"H Holte","year":"2013","unstructured":"Holte H, Lepp\u00e4 S, Bj\u00f6rkholm M, Fluge, Jyrkki\u00f6 S, Delabie J, et al. Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell\/follicular grade 3 lymphoma patients: Results of a phase II Nordic lymphoma group study. Ann Oncol [Internet]. 2013;24:1385\u201392. https:\/\/doi.org\/10.1093\/annonc\/mds621.","journal-title":"Ann Oncol [Internet]"},{"key":"931_CR11","doi-asserted-by":"publisher","first-page":"7821","DOI":"10.1038\/sj.onc.1208909","volume":"24","author":"AY Chan","year":"2005","unstructured":"Chan AY, Coniglio SJ, Chuang YY, Michaelson D, Knaus UG, Philips MR, et al. Roles of the Rac1 and Rac3 GTPases in human tumor cell invasion. Oncogene. 2005;24:7821\u20139.","journal-title":"Oncogene"},{"key":"931_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/841769","volume":"2015","author":"U R\u00fcetschi","year":"2015","unstructured":"R\u00fcetschi U, Stenson M, Hasselblom S, Nilsson-Ehle H, Hansson U, Fagman H, et al. SILAC-based quantitative proteomic analysis of diffuse large B-cell lymphoma patients. Int J Proteom. 2015;2015:1\u201312.","journal-title":"Int J Proteom"},{"key":"931_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-37273-4","volume":"9","author":"LM Fornecker","year":"2019","unstructured":"Fornecker LM, Muller L, Bertrand F, Paul N, Pichot A, Herbrecht R, et al. Multi-omics dataset to decipher the complexity of drug resistance in diffuse large B-cell lymphoma. Sci Rep. 2019;9:1\u20139.","journal-title":"Sci Rep"},{"key":"931_CR14","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1111\/bjh.15259","volume":"181","author":"S Bram Ednersson","year":"2018","unstructured":"Bram Ednersson S, Stenson M, Stern M, Enblad G, Fagman H, Nilsson-Ehle H, et al. Expression of ribosomal and actin network proteins and immunochemotherapy resistance in diffuse large B cell lymphoma patients. Br J Haematol. 2018;181:770\u201381.","journal-title":"Br J Haematol"},{"key":"931_CR15","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.2174\/0929867323666160418114600","volume":"23","author":"M Buck","year":"2016","unstructured":"Buck M, Gouwy M, Wang J, Snick J, Opdenakker G, Struyf S, et al. Structure and expression of different serum amyloid A (SAA) variants and their concentration-dependent functions during host insults. Curr Med Chem. 2016;23:1725\u201355.","journal-title":"Curr Med Chem"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00931-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00931-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00931-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T07:02:37Z","timestamp":1698303757000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00931-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,26]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["931"],"URL":"https:\/\/doi.org\/10.1038\/s41408-023-00931-6","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,26]]},"assertion":[{"value":"28 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"BH holds shares from Novo Nordisk A\/S and Genmab A\/S. Novo Nordisk A\/S and Genmab A\/S had no influence on the study design, analyses, and reporting of the results. HH: Novartis: Advisory Board; Genmab: Safety Committee; Gilead: Consultancy; Roche: Advisory Board, Consultancy; Takeda: Advisory Board; Incyte: Advisory Board Committee; Nordic Nanovector: Safety Committee. SL: <i>Incyte*:<\/i> Consultancy, Honoraria; <i>Roche*:<\/i> Consultancy, Honoraria, Research Funding; <i>Genmab<\/i>*: Research Funding, <i>Orion*:<\/i> Consultancy, <i>Novartis*:<\/i> Consultancy, Research Funding, Honoraria; <i>Bayer*:<\/i> Research Funding; <i>Celgene*:<\/i> Consultancy, Research Funding. <i>Gilead*:<\/i> Consultancy. *Not related to this study. JMJ: <i>Incyte*:<\/i> Consultancy, <i>Roche*:<\/i> Consultancy; <i>Orion*:<\/i>Consultancy,<i>Novartis*:<\/i> Consultancy, C<i>elgene*:<\/i> Consultancy, Research Funding. <i>Gilead*:<\/i> Consultancy. <i>SOBI*:<\/i> Consultancy. <i>Abbvie*:<\/i> Consultancy *Not related to this study. All other authors declare no conflict of interest and all authors declare no competing financial interest in relation to the work described.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"161"}}